Eagle Asset Management Inc. decreased its position in shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) by 3.5% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 389,722 shares of the company’s stock after selling 14,160 shares during the quarter. Eagle Asset Management Inc.’s holdings in Biohaven Pharmaceutical were worth $37,834,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Capital International Investors increased its position in Biohaven Pharmaceutical by 4.6% during the first quarter. Capital International Investors now owns 5,578,232 shares of the company’s stock worth $381,272,000 after buying an additional 247,254 shares during the period. BlackRock Inc. grew its stake in shares of Biohaven Pharmaceutical by 7.3% in the 1st quarter. BlackRock Inc. now owns 3,783,554 shares of the company’s stock valued at $258,608,000 after purchasing an additional 258,603 shares during the last quarter. Stifel Financial Corp grew its stake in shares of Biohaven Pharmaceutical by 0.9% in the 1st quarter. Stifel Financial Corp now owns 2,564,822 shares of the company’s stock valued at $175,306,000 after purchasing an additional 22,348 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Biohaven Pharmaceutical by 46.3% in the first quarter. Bank of New York Mellon Corp now owns 1,187,193 shares of the company’s stock valued at $81,145,000 after buying an additional 375,612 shares in the last quarter. Finally, Armistice Capital LLC boosted its stake in shares of Biohaven Pharmaceutical by 74.8% in the first quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock valued at $68,350,000 after buying an additional 428,000 shares in the last quarter. 92.14% of the stock is currently owned by institutional investors.
A number of research firms recently weighed in on BHVN. UBS Group downgraded Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating and lifted their price target for the company from $108.00 to $109.00 in a research note on Tuesday, August 10th. Canaccord Genuity lifted their price target on Biohaven Pharmaceutical from $101.00 to $150.00 and gave the company a “buy” rating in a research note on Tuesday, August 3rd. Cantor Fitzgerald boosted their target price on Biohaven Pharmaceutical from $151.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, September 13th. Mizuho boosted their target price on Biohaven Pharmaceutical from $92.00 to $134.00 and gave the stock a “buy” rating in a research report on Monday, July 12th. Finally, HC Wainwright boosted their target price on Biohaven Pharmaceutical from $111.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 8th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $124.27.
Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings results on Sunday, August 8th. The company reported ($3.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.77) by ($0.46). The firm had revenue of $92.93 million during the quarter, compared to the consensus estimate of $85.85 million. During the same period last year, the business posted ($2.55) earnings per share. The firm’s revenue was up 858.3% on a year-over-year basis. As a group, analysts forecast that Biohaven Pharmaceutical Holding Company Ltd. will post -12.17 EPS for the current fiscal year.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators.
Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN).
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.